Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CES2 | O00748 | 1/20 | 0.39 |
| ▸ | CES1 | P23141 | 1/20 | 0.39 |
| ▸ | SLC6A2 | P23975 | 3/20 | 0.39 |
| ▸ | CHRNA1 | P02708 | 1/20 | 0.39 |
| ▸ | CHRNB1 | P11230 | 1/20 | 0.39 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.39 |
| ▸ | CHRNB4 | P30926 | 1/20 | 0.39 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.39 |
| ▸ | CHRNA3 | P32297 | 1/20 | 0.39 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.39 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.39 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22443547 | 1.00 | CES2 (0.39) | CES2CES1SLC6A2CHRNA1CHRNB1 | |
| SCHEMBL22443532 | 1.00 | CES2 (0.39) | CES2CES1SLC6A2CHRNA1CHRNB1 | |
| SCHEMBL31010947 | 1.00 | CES2 (0.39) | CES2CES1SLC6A2CHRNA1CHRNB1 | |
| SCHEMBL22443536 | 1.00 | CES2 (0.39) | CES2CES1SLC6A2CHRNA1CHRNB1 | |
| SCHEMBL22443634 | 1.00 | CES2 (0.39) | CES2CES1SLC6A2CHRNA1CHRNB1 | |
| SCHEMBL22443731 | 1.00 | CES2 (0.39) | CES2CES1SLC6A2CHRNA1CHRNB1 | |
| SCHEMBL22443636 | 1.00 | CES2 (0.39) | CES2CES1SLC6A2CHRNA1CHRNB1 | |
| SCHEMBL22443545 | 1.00 | CES2 (0.39) | CES2CES1SLC6A2CHRNA1CHRNB1 | |
| Hydrochloric Acid SCHEMBL22443587 | 0.99 | CES2 (0.38) | CES2CES1SLC6A2CHRNA1CHRNB1 | |
| Hydrochloric Acid SCHEMBL22443476 | 0.99 | CES2 (0.38) | CES2CES1SLC6A2CHRNA1CHRNB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220152004-A1 | HETEROCYCLYL(PHENYL)METHANOL COMPOUNDS USEFUL IN THE TREATMENT OF HYPERGLYCAEMIA | ATROGI AB (SE) | 2022-05-19 | — | — | US | disclosed |
| EP-3941468-A1 | HETEROCYCLYL(PHENYL)METHANOL COMPOUNDS USEFUL IN THE TREATMENT OF HYPERGLYCAEMIA | Atrogi AB (SE) | 2022-01-26 | — | — | EP | disclosed |
| WO-2020188301-A1 | HETEROCYCLYL(PHENYL)METHANOL COMPOUNDS USEFUL IN THE TREATMENT OF HYPERGLYCAEMIA | ATROGI AB (SE) | 2020-09-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220152004-A1 | HETEROCYCLYL(PHENYL)METHANOL COMPOUNDS USEFUL IN THE TREATMENT OF HYPERGLYCAEMIA | GPR119, SLC5A1, SLC5A2 | CES2 1357/4885CES1 1040/4885SLC6A2 1338/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.